The first purpose-built tool for open endograft explant
FDA DE NOVO AUTHORIZED · DEN250033 · PRODUCT CODE SHR · RX ONLY
XplantR™ frees a failed or infected EVAR stent graft from the aorta in under 90 seconds on average in multicenter simulated-use testing. One single-use, atraumatic instrument replaces cut syringes, orthopedic wire cutters and clamp-and-pull.
Co-invented with Kellie R. Brown, MD, FACS, DFSVS, Professor of Vascular and Endovascular Surgery, Medical College of Wisconsin. Inventory is available to order today.
Inventory is available for ordering today.
The Problem With Current Explant Techniques
Published literature confirms the frustration:
Dubois et al. (Journal of Vascular Surgery, Vol. 74) found the syringe resheathing technique was "rarely reported" and "often unsuccessful" in grafts that had been in place for some time.
Roughly 5% of EVAR grafts eventually require open surgical explant due to failure or infection. Until now, surgeons have relied on improvised tools — modified syringes, orthopedic wire cutters, hemostats — that are bulky, inconsistent and potentially traumatic to the aortic intima.
37% major postoperative complication rate with ad-hoc tools · 9.6% 30-day mortality after open conversion (vs 3.9% for primary open repair) · up to 43% when emergent.
Sources: published NSQIP and single/multi-institutional series on open EVAR conversion outcomes; Erdely et al., multicenter simulated-use validation (submitted).
Arnaoutakis et al. (Journal of Vascular Surgery, Vol. 69) tried the syringe technique in two cases and found it "of limited help."
Extended suprarenal cross-clamp time — a direct consequence of difficult explants — has been linked to high morbidity and mortality in late EVAR conversion.
Introducing the XplantR
Designed with Kellie R. Brown, MD, FACS, DFSVS, Professor of Vascular and Endovascular Surgery at the Medical College of Wisconsin, XplantR™ was built around one principle: make explant SAFE.
Simple — Collapses the stent graft within a protective bull-nose cylinder, preventing vessel wall injury during withdrawal. No blades, no cutting mechanism.
Atraumatic — The bull-nose leading edge and tapered lumen minimize arterial disruption. Released suprarenal barbs are constrained within the device, protecting the vessel and OR staff from sharps exposure.
Fast — A single-device workflow: under 90 seconds average explant time in multicenter simulated-use testing (30 surgeons, 120 explants), versus 10–20+ minutes with ad-hoc methods.
Effective — The curved, open-inner-curve design improves access and visibility. Intimal inspection of all 120 simulated explants found no damage beyond the original suprarenal fixation puncture marks.
Bench and simulated-use data, not clinical outcomes. Evaluated with Medtronic Endurant II AUI and Cook Zenith Flex stent-graft systems.
FDA De Novo authorized. A new device category, and XplantR is its predicate.
De Novo DEN250033, granted April 17, 2026 · Class II · Product Code SHR · Available to order today.
U.S. Patent Nos. 11,351,047 and 12,396,871; JP 7,814,387; EP 4,240,293; AU 2021373636; additional applications pending.
Standard Explant Educational Video
Tissue Ingrowth Complicating Explant
Ready to simplify your next explant?
Whether you are a vascular surgeon evaluating XplantR, a supply chain manager or a vascular surgery coordinator, we would like to hear from you. Orders ship from sterilized stock in 1–2 business days.
Value analysis committee? Regulatory facts, sizing and review documents are on our For Hospitals page.
Brian Thorson, Founder · (262) 219-9162 · brian@hjarta.care · Purchase orders: order@hjartacare.org
